Increasing demand for injectable pharmaceutical products, advanced applications of combination therapies for the management of diseases, rising prevalence of chronic and lifestyle associated diseases, benefits of prefilled syringes over traditional vial and syringe packaging systems, and technological advancements in syringes are the major factors driving the growth of the prefilled syringes market globally.
Prefilled syringe drug delivery systems are frequently used in the treatment of diabetes, rheumatoid arthritis, anaphylaxis, and other diseases, such as multiple sclerosis, anemia, and psoriasis. The application of prefilled syringes for diabetes is expected to lead the global market, advancing at a CAGR of 9.0% during the forecast period. Increasing prevalence of diabetes across the world is the key factor contributing in the growth of the prefilled syringes market. This is substantiated by the fact that, according to the World Health Organization (WHO), the prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014, globally.
Request to sample: https://www.psmarketresearch.com/market-analysis/prefilled-syringes-market/report-sample
During the forecast period, the prefilled syringes market is forecasted to witness the fastest growth in APAC, at a CAGR of 9.6%. This growth is attributed to the rising geriatric population, and surge in the prevalence of different chronic diseases in the region. According to the UN publication, World Population Aging Report 2017, the population aged 60 years and above is expected to increase from 10.0% in 2010 to approximately 25.0% by 2050. This increase in the aging population is expected to create high demand for prefilled syringes, to eliminate the occurrence of various chronic diseases among the aged population.
Send Enquiry: https://www.psmarketresearch.com/send-enquiry?enquiry-url=prefilled-syringes-market
The companies operating in the prefilled syringes industry are getting government approvals for various drugs used in syringes to increase their market share. For instance, in August 2018, Bristol-Myers Squibb Company received United States Food and Drug Administration (USFDA) approval for Opdivo (nivolumab), as the first and only Immuno-Oncology treatment option for patients with metastatic small cell lung cancer (SCLC), whose cancer has progressed after platinum-based chemotherapy.
Some of the other key players operating in the prefilled syringes industry are Becton, Dickinson and Company, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Bayer AG, Pfizer Inc., F. Hoffman-La Roche AG, and Novartis AG.
